Returning to productivity post COVID-19
Accenture's Brad Michel considers how life sciences companies can begin to re-open as we tentatively move to easing lockdown restrictions
13th May 2020
Web Exclusives
Design isn’t a fishhook, it’s Velcro
GSK's Andrew Barraclough considers why brands should make design core to their strategy
30th April 2020
Decoding the microbiome
Decoding the microbiome will be an important facet of precision medicine, helping to find the areas of research it could complement and extend
18th April 2020
Transforming clinical trials during COVID-19
While the effort to treat and manage COVID-19 is underway, here’s how companies can also stay focused on developing treatments for all patients
14th April 2020
Six 2020 predictions for real-world evidence
What can we expect to see for real world evidence in 2020 and beyond?
20th March 2020
The disproportional economic impact of cancer on women
More than half of women take home less pay after a cancer diagnosis. It is time to talk about the ‘ripple effect’ of a cancer diagnosis, says Pfizer's Dr Olivia Ashman
8th March 2020
Rare disease day exclusive
PharmaTimes talks to Biogen's Natalie Ghafoor about her role and views on the rare disease landscape
29th February 2020
After February 29
Rare Disease Day is a fixture in the calendar not only for affected patients and families, and patient advocacy organisations, but also the myriad of other stakeholders that make up the rare disease ecosystem
28th February 2020
The rare disease challenge
Natalie Douglas looks at the ongoing needs and challenges for rare disease patients and their care moving forward
27th February 2020
The promise of IoMT
How the Internet of Medical Things (IoMT) can streamline clinical ops – and why it’s worth the investment
25th February 2020
How tech advancements are impacting cancer research
Giving cancer research the best chance of success
13th February 2020
Treating a label like a machine Is transformational
The pharmaceutical industry has a head-start on heavyweight compliance and legacy product transparency requirements but do medical device manufacturers bring new advantage from an engineering mindset?
13th February 2020
The fork in the road
Gilead's Hilary Hutton-Squire on industry, innovation, and the NICE Methods Review
6th February 2020
The dangers of reduced market choice in life sciences
Industry consolidation continues apace, harming competition and reducing choice. Alan White warns that customers now need to be more discerning when assessing suppliers’ relative value.
4th February 2020
World Cancer Day exclusive: Putting the ‘personal’ into personalised medicine
Geoff Twist, managing director for Roche Diagnostics UK and Ireland, on working towards cancer treatment that's fit for the future
4th February 2020
